Sharma Alok, Ngan Bo-Yee, Sándor George K B, Campisi Paolo, Forte Vito
Department of Otolaryngology Surgery, Hospital for Sick Children, Toronto, Ontario, Canada.
J Pediatr Surg. 2008 Sep;43(9):1596-604. doi: 10.1016/j.jpedsurg.2008.02.001.
Aggressive fibromatosis in children is a rare, benign condition that is locally infiltrative and destructive. It often presents as a rapidly growing, painless lump in the head and neck region. To date, only small series and case reports have been reported, and the management of the condition remains unclear. Recently, nuclear beta-catenin expression has been suggested as a tumor-specific marker for aggressive fibromatosis (desmoid).
The aims of the study were to review our experience of the presentation, management, and treatment outcome of pediatric aggressive fibromatosis in the head and neck and to identify the presence of the desmoid tumor marker beta-catenin within this population.
The study was conducted as a retrospective case review of children diagnosed with aggressive fibromatosis in the head and neck for a period of 20 years and a review of the literature. Pathologic review of the original tumor specimens was undertaken for evidence of positive tumor margins and presence of nuclear beta-catenin expression.
A total of 10 patients (6 males, 4 females) were identified. The age at presentation ranged from 12 months to 14 years. In total, 8 patients were treated with surgery alone. This included 7 patients with extension of the tumor to the resection margin; all had good long-term outcomes with no disease progression. Two patients received chemoradiotherapy, one as primary treatment, and the other as adjuvant treatment after gross incomplete resection. Both resulted in poor outcomes requiring further treatments. Within our series of pediatric fibromatosis, only 4 cases (40%) had positive results for any nuclear beta-catenin expression, and 6 (60%) of 10 patients had negative results for beta-catenin.
Our experience is that total gross resection and preservation of form and function is of higher priority than achieving a negative resection margin. Pediatric fibromatosis though aggressive is still a benign condition, and careful thought should be taken before considering adjuvant chemoradiotherapy. Nuclear beta-catenin expression should not be considered a specific tumor marker for pediatric aggressive fibromatosis of the head and neck. Pediatric aggressive fibromatosis in this region may be a distinct subtype of desmoid tumor from its adult form.
儿童侵袭性纤维瘤病是一种罕见的良性疾病,具有局部浸润性和破坏性。它常表现为头颈部迅速生长的无痛性肿块。迄今为止,仅有小样本系列研究和病例报告,该疾病的治疗方法仍不明确。最近,核β-连环蛋白表达被认为是侵袭性纤维瘤病(硬纤维瘤)的肿瘤特异性标志物。
本研究旨在回顾我们在儿童头颈部侵袭性纤维瘤病的表现、治疗及治疗结果方面的经验,并确定该人群中硬纤维瘤肿瘤标志物β-连环蛋白的存在情况。
本研究通过对20年间诊断为头颈部侵袭性纤维瘤病的儿童进行回顾性病例分析,并复习相关文献。对原始肿瘤标本进行病理检查,以确定肿瘤切缘阳性及核β-连环蛋白表达情况。
共确定10例患者(6例男性,4例女性)。就诊年龄为12个月至14岁。总共8例患者仅接受了手术治疗。其中7例肿瘤侵犯至手术切缘;所有患者长期预后良好,无疾病进展。2例患者接受了放化疗,1例作为初始治疗,另1例在大体切除不完全后作为辅助治疗。两者预后均较差,需要进一步治疗。在我们的儿童纤维瘤病系列中,仅4例(40%)核β-连环蛋白表达呈阳性,10例患者中有6例(60%)β-连环蛋白表达呈阴性。
我们的经验是,完整切除肿瘤并保留形态和功能比获得阴性手术切缘更为重要。儿童纤维瘤病虽然具有侵袭性,但仍是良性疾病,在考虑辅助放化疗前应谨慎权衡。核β-连环蛋白表达不应被视为儿童头颈部侵袭性纤维瘤病的特异性肿瘤标志物。该区域的儿童侵袭性纤维瘤病可能是硬纤维瘤的一种与成人形式不同的亚型。